Codexis Inc (CDXS): Rasio kapitalisasi marang pendapatan
On GURU.Markets, the P/S divergence from the historical average demonstrates market expectations, where the value of 1.40 serves as the current indicator. The Codexis, Inc. (CDXS) business is exposed to risks due to its dependence on major customers and lengthy development cycles. However, the CodeEvolver platform makes their expertise indispensable, reducing costs for partners. An impeccable reputation as a biocatalysis leader ensures the company maintains the full trust of global pharma behemoths.
Rincian analitis perusahaan Codexis, Inc. (CDXS)
- rega lan prakiraan konsensus rega:
- data kapitalisasi bursa:
- rincian valuasi buku bisnis:
- statistik kawajiban utang lan likuiditas:
Rasio Total Utang marang Ekuitas Codexis, Inc.|CDXS - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang modal codexis.com|CDXS - Gunggung utang perusahaan|Rasio utang marang nilai buku Codexis Bio|CDXS - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Codexis, Inc.|Rasio likuiditas darurat codexis.com
- data bathi bisnis lan rasio investasi:
CDXS - Bathi resik perusahaan|Prakiraan bathi resik Codexis, Inc.|CDXS - Pangali P/E|Pangali Forward P/E codexis.com|CDXS - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Codexis Bio|CDXS - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Codexis, Inc.|CDXS - Bathi resik saben saham (EPS TTM)|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan codexis.com|CDXS - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Codexis, Inc.
- indikator pendapatan dodolan lan penghasilan bisnis:
Ringkesan analitik perusahaan:Codexis Inc (CDXS)
The P/S multiple determines the market value of one dollar of revenue, allowing for an assessment of the business premium regardless of current earnings. The price-to-sales ratio trend reflects market confidence in the commercialization of the R&D pipeline of Codexis, Inc. (CDXS), where any decline in the indicator may signal decreasing demand for engineered enzymes within the biopharmaceutical sector.
Pesaing Codexis, Inc.
Koefisien rega marang pendapatan Tempus AI|Rasio rega marang pendapatan Qiagen QGEN|IONS: Rasio kapitalisasi marang pendapatan|Repligen Corp. - Multiplikator P/S|Avidity Corp (RNA) - Kapitalisasi marang pendapatan|CRSP (CRISPR Therapeutics AG) - Kapitalisasi marang pendapatan|WGS - Koefisien rega marang pendapatan|RARE (Ultragenyx) - Multiplikator P/S|Kapitalisasi marang pendapatan Beam Therapeutics Inc (BEAM)|Multiplikator P/S SRPT|Twist Bioscience Corp - Rasio kapitalisasi marang pendapatan|10x Genomics, Inc. - Kapitalisasi marang pendapatan|NTLA: Rasio kapitalisasi marang pendapatan|STOK - Rasio rega marang pendapatan|Koefisien rega marang pendapatan BioLife Solutions Inc BLFS|WVE: Multiplikator P/S|Rasio kapitalisasi marang pendapatan MAZE|Rasio rega marang pendapatan Sionna Therapeutics Inc|Rasio kapitalisasi marang pendapatan PRME (primemedicine.com)|Multiplikator P/S TSHA|Multiplikator P/S uniQure NV (QURE)|Multiplikator P/S MGTX (MeiraGTx PLC)|RGNX - Kapitalisasi marang pendapatan|SLDB - Rasio rega marang pendapatan|Rega marang dodolan ocugen.com|PACB: Multiplikator P/S|Rasio kapitalisasi marang pendapatan BNTC|DSGN (Design Pharma) - Multiplikator P/S|Rega marang dodolan Rocket Corp RCKT|Kapitalisasi marang pendapatan FDMT (4D Molecular Therapeutics)|lexeotx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S KRRO (Korro Bio)|Koefisien rega marang pendapatan Editas Medicine Inc (EDIT)|SLN - Rasio rega marang pendapatan|Koefisien rega marang pendapatan ProQR Therapeutics N.V. PRQR|SGMO (Sangamo Therapeutics) - Kapitalisasi marang pendapatan|Nautilus Bio - Rasio kapitalisasi pasar marang pendapatan|MGX (Metagenomi) - Multiplikator P/S|precisionbiosciences.com (DTIL) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Generation Bio Co. (GBIO)|Boundless Bio Inc - Rasio kapitalisasi marang pendapatan|Multiplikator P/S XCUR (Exicure)|IMNN - Kapitalisasi marang pendapatan|PHIO: Kapitalisasi marang pendapatan|Koefisien rega marang pendapatan Mustang Bio, Inc. MBIO|RNAZ: Multiplikator P/S|Kapitalisasi marang pendapatan Bionano Genomics|APDN (Applied DNA Sciences) - Multiplikator P/S|Rasio kapitalisasi marang pendapatan BLUE (bluebirdbio.com)|Kapitalisasi marang pendapatan IPA (ImmunoPrecise Antibodies)|Omega Therapeutics Inc - Rasio kapitalisasi marang pendapatan|Rasio rega marang pendapatan Singular Genomics Systems Inc OMIC|Koefisien rega marang pendapatan Regulus (RGLS)|Syros Pharmaceuticals - Multiplikator P/S|TBIO (telesisbio.com) - Rasio kapitalisasi marang pendapatan|TRACON Pharmaceuticals, Inc. (TCON) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan UBX
